Current market catalysts

Dell Technologies shares are trading higher following reports suggesting the company wants to raise $4 billion from a bond sale.

Centerspace shares are trading higher after the company announced it entered into a definitive merger with Independence Realty Trust, under which Centerspace and IRT will combine in an all-stock transaction. The combined company is expected to have a pro forma equity market capitalization of approximately $5.0 billion and a total enterprise value of approximately $8.1 billion.

JP Morgan Assumes Lithium Americas at Overweight, Announces Price Target of C$8

AbbVie Exec Says Balance Sheet And Growth Runway Allow Company To Consider Both Early- And Late-Stage Business Development Opportunities

Oppenheimer Maintains Outperform on Zurn Elkay Water Solns, Raises Price Target to $60

UnitedHealth Group shares are trading lower. A report suggested the company sold its interest in Florida WellMed clinics to TPG.

Oppenheimer Maintains Outperform on Ralliant, Raises Price Target to $80

AdaptHealth shares are trading lower. The company appointed Harriss T. Currie as its Chief Financial Officer.

Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says

Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.

HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target

GameChange Energy Says Subsidiary GameChange Solar Filed Patent Infringement Lawsuit Against Nextpower Over High-Tilt Stow Technology, Seeking Injunctive Relief And Damages

JP Morgan Assumes Lithium Americas at Overweight, Announces Price Target of $6

Democratic Senators Urge Delta Air Lines In A Letter To Remain Neutral In Flight Attendant Union Organizing Effort

$1000 Invested In Equinix 15 Years Ago Would Be Worth This Much Today

Equinix (NASDAQ:EQIX) has outperformed the market over the past 15 years by 4.2% on an annualized basis producing an average annual return of 17.24%. Currently, Equinix has a market capitalization of $102.74 billion.

Jersey Mike’s Subs shares are trading higher despite reporting a year-over-year decrease in its Q2 net income and worse-than-expected Q2 sales results. The company's CEO said that traffic is accelerating despite industrywide weakness, supporting Q2 same-store sales growth of 2.3% year-over-year.

Barnes & Noble Education shares are trading lower after the company reported worse-than-expected Q1 financial results.

Oppenheimer Maintains Outperform on IDEX, Raises Price Target to $270

Elon Musk Spooked Howmet. GE Just Validated the Bull Case

Elon Musk's SpaceX plans and GE's $11.75B deal suggest turbine blade shortages remain one of aerospace's biggest bottlenecks.

BridgeBio Oncology Therapeutics shares are trading lower after the company announced new clinical data for KRASG12C inhibitor BBO-8520.

Memory Is the New ‘King’ of Chips, Taking Over 50% of Semiconductor Revenue, Susquehanna Says

Susquehanna says memory now drives 50%-55% of semiconductor revenue as AI demand reshapes chip spending and boosts Micron.

Oppenheimer Maintains Outperform on Ormat Technologies, Raises Price Target to $145

TD Cowen Maintains Hold on Amphenol, Lowers Price Target to $90

TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55

Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

Reported Earlier: 'HSBC to wind down German business for transaction services, over 300 jobs to be phased out' - Reuters

Bitcoin Holds $79,000, Defying Fed Hike Fears: What Is Going On?

Wintermute sees capital rotating from stalled stocks into crypto, with BTC resilient, ETF inflows strong, and $72,000 key support.

Signet CEO Says ‘Value’ Will Rule Holiday Shopping As Consumers Feel the Squeeze

Signet Jewelers (SIG) stock surges 19% on Q2 EPS beat, margin expansion, and a boosted FY27 outlook despite flat sales.

Why Is Strategy Stock Surging on Wednesday?

Strategy stock rose Wednesday alongside Bitcoin gains, a Canaccord Genuity price forecast raise to $179, and sold-out merchandise.

BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain

BridgeBio Pharma shares 52-week data on oral infigratinib for achondroplasia, showing improvements in sleep apnea, otitis media, and BMI.

Wells Fargo Maintains Overweight on ServiceTitan, Lowers Price Target to $105